Biocon’s Kirsty, a biosimilar to Novolog, gets U.S. FDA approval as an interchangeable rapid-acting insulin for diabetes management.

• Available as a prefilled pen and vial, Kirsty expands Biocon’s insulin range alongside Semglee in the U.S., Europe, and Canada.
• U.S. insulin aspart market valued at $1.9 billion in 2024; nearly 38.4 million Americans live with diabetes.
• Biocon aims to improve insulin access, affordability, and treatment choices globally with the Kirsty launch.